Public Employees Retirement System of Ohio Purchases Shares of 7,564 Medpace Holdings, Inc. $MEDP

Public Employees Retirement System of Ohio acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 7,564 shares of the company’s stock, valued at approximately $4,006,000.

Other institutional investors have also recently bought and sold shares of the company. Johnson Financial Group Inc. acquired a new stake in Medpace during the second quarter worth about $27,000. Geneos Wealth Management Inc. raised its holdings in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the period. Elyxium Wealth LLC acquired a new position in Medpace during the fourth quarter valued at approximately $30,000. Jones Financial Companies Lllp purchased a new stake in Medpace during the second quarter worth approximately $30,000. Finally, Allied Private Wealth LLC acquired a new position in shares of Medpace during the 2nd quarter valued at $31,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $593.39 on Friday. The stock has a fifty day moving average price of $573.38 and a two-hundred day moving average price of $498.87. The firm has a market cap of $16.56 billion, a P/E ratio of 34.78, a PEG ratio of 2.65 and a beta of 1.15. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter last year, the firm posted $3.10 earnings per share. Medpace’s revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on MEDP. Leerink Partners set a $620.00 price target on shares of Medpace in a report on Thursday, July 23rd. BMO Capital Markets upped their target price on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and lifted their price target for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Mizuho upped their price objective on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Finally, Truist Financial lifted their target price on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Medpace presently has an average rating of “Hold” and a consensus price target of $595.20.

Insiders Place Their Bets

In related news, CEO August Troendle sold 27,174 shares of the business’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $618.79, for a total transaction of $16,814,999.46. Following the completion of the transaction, the chief executive officer owned 561,195 shares of the company’s stock, valued at approximately $347,261,854.05. The trade was a 4.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Susan Burwig sold 7,500 shares of the stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the completion of the sale, the vice president owned 62,984 shares of the company’s stock, valued at approximately $37,790,400. The trade was a 10.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 134,471 shares of company stock worth $82,151,311 over the last quarter. 20.50% of the stock is currently owned by company insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.